Human epidermal growth factor receptor 2 (HER2/neu) supraexpression in the mammary tumors

被引：0
作者：
Moise, M. [1 ]
Motoc, A. [1 ]
Raducan, Andreea [2 ]
Raducan, S. [1 ]
Niculescu, V. [1 ]
Niculescu, M. [1 ]
机构：
[1] Victor Babes Univ Med & Pharm, Dept Anat & Embryol, Timisoara 300041, Romania
[2] Victor Babes Univ Med & Pharm, Dept Pathophysiol, Timisoara 300041, Romania
来源：
ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY | 2011年 / 52卷 / 03期
关键词：
mammary tumors; HER2/neu supraexpression; immunohistochemistry; NEGATIVE BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; HER-2/NEU GENE; IN-SITU; AMPLIFICATION; ONCOGENE; THERAPY; ERBB-2; OVEREXPRESSION; CARCINOMA;
D O I：
暂无
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
A series of morphological and molecular factors can be used in order to appreciate the prognostic of mammary cancer. A multitude of molecular factors has been investigated in order to identify a prognostic factor, one of the most studied factors being HER2 (human epidermal receptor growth factor). For this purpose, we have carried out an immunohistochemical research, in order to determine the correlation between the presence of morphological factors in tumor formation, different stages of evolution, and the response to therapy. We have correlated HER2 expression with the histological type of carcinomas, the histological differential degree, ER, PR immunohistochemical expression, as well as the available clinical data. Within the studied carcinomas, we have identified a number of 98/156 (62.8%) carcinomas HER2/neu negative, out of which 74/156 (47.4%) did not reveal the presence of HER2/neu and 24/156 (15.4%) have been quantified as being 1+. The HER2/neu supraexpression was encountered in 58/156(37.17%) cases: in 34/156 (21.8%) cases the immunostaining was interpreted as being 2+ and in 24/156 (15.4%) cases it was interpreted as being 3+. HER2/neu supraexpression should be routinely determined through immunohistochemical methods in all primary mammary tumors, especially in those poorly differentiated.
引用
收藏
页码：1101 / 1105
页数：5
相关论文
共 50 条
[31]   Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu [J].
Roh, H ;
Pippin, J ;
Boswell, C ;
Drebin, JA .
JOURNAL OF SURGICAL RESEARCH, 1998, 77 (01) :85-90
[32]   Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma [J].
Thomas, DG ;
Giordano, TJ ;
Sanders, D ;
Biermann, S ;
Sondak, VK ;
Trent, JC ;
Yu, D ;
Pollock, RE ;
Baker, L .
CANCER, 2005, 103 (04) :830-838
[33]   Impact of immunohistochemistry staining conditions on the incidence of human epidermal growth factor receptor 2 (HER2)-low breast cancer [J].
Kim, Min Chong ;
Kwon, Sun Young ;
Jung, Hye Ra ;
Bae, Young Kyung .
VIRCHOWS ARCHIV, 2024, 485 (06) :1117-1125
[34]   Study of the Effect of Neoadjuvant Chemotherapy on the Status of Her2/neu [J].
Skalova, H. ;
Dundr, P. ;
Povysil, C. ;
Velenska, Z. ;
Petruzelka, L. ;
Tvrdik, D. .
FOLIA BIOLOGICA, 2011, 57 (05) :191-199
[35]   Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff [J].
Wrobel, Agata ;
Vandenberghe, Michel ;
Scott, Marietta ;
Jones, Frances ;
Matsuo, Tsuyoshi ;
Boothman, Anne-Marie ;
Whiteley, Jessica ;
Barker, Craig .
DIAGNOSTIC PATHOLOGY, 2025, 20 (01)
[36]   Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer [J].
Finn, Richard S. ;
Press, Michael F. ;
Dering, Judy ;
Arbushites, Michael ;
Koehler, Maria ;
Oliva, Cristina ;
Williams, Lisa S. ;
Di Leo, Angelo .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) :3908-3915
[37]   Human Epidermal Growth Factor Receptor 2 (HER2) Extracellular Domain Levels Are Associated with Progression-Free Survival in Patients with HER2-Positive Metastatic Breast Cancer Receiving Lapatinib Monotherapy [J].
Lipton, Allan ;
Leitzel, Kim ;
Ali, Suhail M. ;
Carney, Walter ;
Platek, Greg ;
Steplewski, Klaudia ;
Westlund, Ron ;
Gagnon, Robert ;
Martin, Anne-Marie ;
Maltzman, Julie .
CANCER, 2011, 117 (21) :5013-5020
[38]   Targeting the Human Epidermal Growth Factor Receptor 2 in Esophageal Cancer [J].
Almhanna, Khaldoun ;
Meredith, Kenneth L. ;
Hoffe, Sarah E. ;
Shridhar, Ravi ;
Coppola, Domenico .
CANCER CONTROL, 2013, 20 (02) :111-116
[39]   Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas [J].
A. Sett ;
B. B. Borthakur ;
U. Bora .
Clinical and Translational Oncology, 2017, 19 :976-988
[40]   Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features [J].
Erman, M ;
Grunenwald, D ;
Penault-Llorca, F ;
Grenier, J ;
Besse, B ;
Validire, P ;
Moret, L ;
Girard, P ;
Le Chevalier, T ;
Sabatier, L ;
Soria, JC .
LUNG CANCER, 2005, 47 (03) :315-323
12345